You are here

Donepezil in the Prevention of Post-Operative Cognitive Decline

Last updated on May 12, 2018

FOR MORE INFORMATION
Study Location
University Hospital, Clarian Health Partners
Indianapolis, Indiana, 46202 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postoperative Complications, Delirium
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
65+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Community-dwelling individuals aged 65 or older

- Scheduled for elective hip or knee replacement at University Hospital

- Mild cognitive impairment, defined as:

- MMSE total score of 27 or less;

- normal performance of the activities of daily living tasks of the Bristol scale
after excluding mobility related difficulties;

- no chart-based dementia diagnosis; and

- no history of ever being on dementia medications such as Memantine or any
cholinesterase inhibitors

- Consent to participate in the study

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Chart-based dementia diagnosis

- MMSE score greater than 27

- Difficulty performing the activities of daily living not related to mobility as
measured by the Bristol scale

- Current or past history of receiving dementia medications such as Memantine or any
cholinesterase inhibitors (Tacrine, Donepezil, Rivastigmine, or Galantamine)

- Metastatic cancer or other comorbid illnesses likely to reduce life expectancy to
under 6 months

- Multiple trauma or pathological fractures requiring acute hip or knee replacement

- Aphasic, blind, or deaf

- Use of neuroleptics one month prior to surgery

- Allergy to donepezil

- Inability to read and complete study tests and forms

- Alcohol or drug dependence, defined as intake of more than 5 units of alcohol daily
during the past 3 months

- Not expected to be discharged from hospital or able to complete the 3-month
postoperative test

- Not competent to make medical decisions

NCT00182845
Pfizer
Completed
Donepezil in the Prevention of Post-Operative Cognitive Decline

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Postoperative Complications, Delirium
NCT00182845
All Genders
65+
Years
Indianapolis, Indiana
Diabetic Foot Ulcer, Diabetes Complications
NCT00312364
All Genders
18+
Years
Multiple Sites
Donepezil in the Prevention of Post-Operative Cognitive Decline
Preventing Post-Operative Cognitive Decline
The purpose of this study is to evaluate the feasibility of using Donepezil to prevent post-operative cognitive decline (POCD) among individuals aged 65 and older who have a baseline mild cognitive impairment (MCI) and are undergoing elective hip or knee replacement.

Up to 65% of elderly patients undergoing hip or knee surgery suffer from declining brain function known as post-operative cognitive decline (POCD). These individuals often stay in the hospital longer, have more complications, and are more likely to die. Recent clinical studies have shown the potential benefit of enhancing the cholinergic system among patients with both Alzheimer's disease and / or vascular dementia. Donepezil is currently being used to treat memory loss in patients with Alzheimer's disease.

This study will recruit 30 cognitively impaired adults aged 65 or older who are scheduled to have elective hip or knee replacement surgery at University Hospital. Participants will be randomized to receive either a three to six week supply of Donepezil or a matching placebo approximately 4 weeks prior to surgery. This study will evaluate the effect of Donepezil on delirium incidence and severity during hospitalization, global cognitive function, length of hospitalization, site of discharge, and adverse drug effects.

All material to be collected will be from interviews, questionnaires, and medical chart review. Some will be at baseline, during hospitalization, and 12 weeks post hospitalization and others will be daily during hospitalization. The International Study of Post-Operative Cognitive Decline battery of tests will be used in assessment, as will the CogHealth computerized battery.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
  • Postoperative Complications
  • Delirium
Drug: Donepezil
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
April 2007
April 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Community-dwelling individuals aged 65 or older
  • Scheduled for elective hip or knee replacement at University Hospital
  • Mild cognitive impairment, defined as:

    • MMSE total score of 27 or less;
    • normal performance of the activities of daily living tasks of the Bristol scale after excluding mobility related difficulties;
    • no chart-based dementia diagnosis; and
    • no history of ever being on dementia medications such as Memantine or any cholinesterase inhibitors
  • Consent to participate in the study

Exclusion Criteria:

  • Chart-based dementia diagnosis
  • MMSE score greater than 27
  • Difficulty performing the activities of daily living not related to mobility as measured by the Bristol scale
  • Current or past history of receiving dementia medications such as Memantine or any cholinesterase inhibitors (Tacrine, Donepezil, Rivastigmine, or Galantamine)
  • Metastatic cancer or other comorbid illnesses likely to reduce life expectancy to under 6 months
  • Multiple trauma or pathological fractures requiring acute hip or knee replacement
  • Aphasic, blind, or deaf
  • Use of neuroleptics one month prior to surgery
  • Allergy to donepezil
  • Inability to read and complete study tests and forms
  • Alcohol or drug dependence, defined as intake of more than 5 units of alcohol daily during the past 3 months
  • Not expected to be discharged from hospital or able to complete the 3-month postoperative test
  • Not competent to make medical decisions
Sexes Eligible for Study: All
65 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00182845
IA0078
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Principal Investigator: Malaz Boustani, MD, MPH Regenstrief Institute, Indiana University Center for Aging Research
National Institute on Aging (NIA)
February 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now